SEC Company Response from HEMOBIOTECH INC (CIK 0001301348) — May 13, 2005
HEMOBIOTECH INC (CIK 0001301348)
Date: May 13, 2005 · CIK: 0001301348 · Accession: 0000930413-05-003590
AI Filing Summary & Sentiment
File numbers found in text: 333-122097
Letter
Re: Hemobiotech, Inc. (the "Company") Registration Statement on Form SB-2 (Registration No. 333-122097) -----------------------------------------------------------------
HEMOBIOTECH, INC. 14221 Dallas Parkway Suite 1500 Dallas, Texas 75254
May 13, 2005
VIA FACSIMILE (202) 942-9585 AND EDGAR -------------------------------------- Securities and Exchange Commission Judiciary Plaza 450 Fifth Street, N.W. Washington, D.C. 20549-0404 Attention: Mr. Daniel Greenspan
Ladies and Gentlemen:
In connection with the Company's request for acceleration with respect to its Registration Statement on Form SB-2 (Registration No. 333-122097), as filed on May 13, 2005, the Company hereby acknowledges that:
o Should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
o The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
o The Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
HEMOBIOTECH, INC.
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
HEMOBIOTECH, INC.
14221 Dallas Parkway
Suite 1500
Dallas, Texas 75254
May 13, 2005
VIA FACSIMILE (202) 942-9585 AND EDGAR
--------------------------------------
Securities and Exchange Commission
Judiciary Plaza 450 Fifth Street, N.W.
Washington, D.C. 20549-0404
Attention: Mr. Daniel Greenspan
Re: Hemobiotech, Inc. (the "Company")
Registration Statement on Form SB-2 (Registration No. 333-122097)
-----------------------------------------------------------------
Ladies and Gentlemen:
In connection with the Company's request for acceleration with respect
to its Registration Statement on Form SB-2 (Registration No. 333-122097), as
filed on May 13, 2005, the Company hereby acknowledges that:
o Should the Securities and Exchange Commission (the
"Commission") or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the
filing;
o The action of the Commission or the staff, acting pursuant to
delegated authority, in declaring the filing effective, does
not relieve the Company from its full responsibility for the
adequacy and accuracy of the disclosure in the filing; and
o The Company may not assert this action as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
Very truly yours,
HEMOBIOTECH, INC.
By: /s/ Arthur P. Bollon
----------------------------------
Arthur P. Bollon
President, Chief Executive Officer
and Chairman
cc: Robert Cohen, Esq.
Anthony J. Marsico, Esq.
Marlene M. Markard, Esq.
</TEXT>
</DOCUMENT>